Intensity Therapeutics Files 8-K

TL;DR

INTENSITY THERAPEUTICS FILES 8-K FOR CORPORATE UPDATES

AI Summary

Intensity Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on events that occurred on August 8, 2025. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws, other events, and financial statements/exhibits. No specific financial figures or significant operational changes were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates corporate governance updates and the submission of financial information, which are standard disclosures for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for corporate updates and does not appear to contain material adverse information.

Key Players & Entities

• INTENSITY THERAPEUTICS, INC. (company) — Registrant
• August 8, 2025 (date) — Earliest event date
• August 12, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of Incorporation
• Shelton, CT (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on Which Registered: Common Stock, $0.0001 par value per share INTS The Nasdaq Sto
• $35,000,000 — value of listed securities of less than $35,000,000 and annual net income of less than $500
• $500,000 m — ,000 and annual net income of less than $500,000 maintain stockholders' equity of at least
• $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"
• $6.6 million — orted, the Company raised approximately $6.6 million in July 2025 from the sale of shares of

Filing Documents

• intensity-20250808.htm (8-K) — 30KB
• amendmenttotheamendedandre.htm (EX-3.1) — 5KB
• 0001567264-25-000081.txt ( ) — 162KB
• intensity-20250808.xsd (EX-101.SCH) — 2KB
• intensity-20250808_lab.xml (EX-101.LAB) — 24KB
• intensity-20250808_pre.xml (EX-101.PRE) — 14KB
• intensity-20250808_htm.xml (XML) — 3KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On August 12, 2025, the Board of Directors of Intensity Therapeutics, Inc. (the "Company"), adopted an amendment (the "Amendment") to the Amended and Restated Bylaws of the Company (the "Bylaws"). The changes to the Bylaws pursuant to the Amendment are effective as of August 12, 2025. The Amendment amends Section 2.7 of the Bylaws, dealing with a quorum at meetings of stockholders, to generally provide that a quorum is at least one-third of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy. Prior to effectiveness of the Amendment, a quorum is a majority of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by the full text of the Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.

01. Other Events

Item 8.01. Other Events. As previously reported, on May 19, 2025, the Company received a deficiency notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market (the "Notice") based on the information provided in the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2025. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and annual net income of less than $500,000 maintain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"). Also as previously reported, the Company raised approximately $6.6 million in July 2025 from the sale of shares of common stock pursuant to its previously announced At-the-Market offering (the "ATM"). On August 7, 2025, the Company filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 stating that based on the Company's balances in cash and cash equivalents as of June 30, 2025, plus the cash raised under the ATM in July 2025, the Company believes that it has at least $2,500,000 in stockholders' equity, as required pursuant to the Stockholders' Equity Requirement. On August 8, 2025, the Company received a letter from Nasdaq stating that based on the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Staff has determined that the Company complies with the Stockholders' Equity Requirement. The letter also stated that if at the time of its next periodic report the Company does not evidence compliance, it may be subject to delisting. At that time, the Staff will provide written notification to the Company, which may then appeal the Staff's determination to a Hearings Panel.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amendment to the Amended and Restated Bylaws, certified as of August 12, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 12, 2025 Intensity Therapeutics, Inc. By: /s/ Lewis H. Bender Name: Lewis H. Bender Title: Chief Executive Officer [ Signature Page to the Form 8-K ] 1

View Full Filing

View this 8-K filing on SEC EDGAR